Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded company in the Unknown sector. Across all available filings, 12 corporate insiders have executed 153 transactions totaling $147.8M, demonstrating a bullish sentiment with $22.6M in net insider flow. The most recent transaction on Jun 27, 2025 involved a sale of 1,176,332 shares valued at $4.9M.
CRVS Insider Activity Summary
Who Is Buying CRVS Stock?
No significant insider buying has been recorded for CRVS in the recent period.
Who Is Selling CRVS Stock?
No significant insider selling has been recorded for CRVS in the recent period.
Is Corvus Pharmaceuticals, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for CRVS is bullish with an Insider Alignment Score of 58/100 and a net flow of $22.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
CRVS Frequently Asked Questions
Understanding CRVS Insider Activity
Insider trading at Corvus Pharmaceuticals, Inc. (CRVS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 12 insiders are actively trading CRVS stock, having executed 153 transactions in the past 90 days. The most active insider is Peter A. Thompson (Executive), who has made 25 transactions totaling $38.8M.
Related Tools
Track Corvus Pharmaceuticals, Inc. Insider Activity
Get notified when executives and directors at CRVS file new Form 4 transactions